
    
      Key objectives of this study include:

        1. To describe efficacy (SVR) in a special population of patients with chronic hepatitis C
           who are not willing or not candidates for IFN-based therapy.

        2. To describe safety, tolerability, and treatment persistency in this patient population
           with advanced liver disease.
    
  